Multiple Sclerosis Prior Authorization Updates
Blue Cross and Blue Shield of Kansas (BCBSKS) continually reviews Prior Authorization (PA) programs and looks for opportunities to improve provider experience.
Effective March 1, 2022, generic Copaxone (glatiramer) and generic Tecfidera (dimethyl fumarate) will no longer be subject to PA. These two generic products may be prescribed when medically necessary without needing to complete the PA process.
Please note, requests for brand-name Copaxone and brand-name Tecfidera will still be subject to PA. Requests for the generic products that exceed FDA labeled dosing will also require a prior authorization. The policy, Multiple Sclerosis Agents, posted on Feb. 1, 2022 for review of the upcoming changes.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative.